title: HDAC inhibitors show benefits in breast cancer.
abstract: One agent reduces tamoxifen resistance in preclinical studies, while lysine acetylation measurements may monitor clinical benefit of a second drug.
authors.forename: Suzanne
authors.initials: S
authors.lastname: Rose
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology*; D004353:Drug Evaluation, Preclinical; D005260:Female; D056572:Histone Deacetylase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans
chemical_list: D056572:Histone Deacetylase Inhibitors